TAS6417

CAS No. 1661854-97-2

TAS6417( —— )

Catalog No. M23746 CAS No. 1661854-97-2

TAS6417 is an EGFR inhibitor and is an efficacious drug candidate for patients with NSCLC.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 178 In Stock
10MG 295 In Stock
25MG 597 In Stock
50MG 954 In Stock
100MG 1467 In Stock
500MG 2952 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    TAS6417
  • Note
    Research use only, not for human use.
  • Brief Description
    TAS6417 is an EGFR inhibitor and is an efficacious drug candidate for patients with NSCLC.
  • Description
    TAS6417 is an EGFR inhibitor and is an efficacious drug candidate for patients with NSCLC (IC50: ranging from 1.1-8.0 nM).
  • In Vitro
    Apoptosis Analysis Cell Line:PC-9, H1975, BID007, BID019, BEAS-2B cells.Concentration:0-10 μM.Incubation Time:24-48 h.Result:Led to apoptosis via inhibition of mutant EGFR.
  • In Vivo
    Animal Model:Mice implanted with NCI-H1975 EGFR D770_N771insSVD xenografts.Dosage:50 and 100 mg/kg.Administration:Orally once daily for 14 days.Result:Showed marked tumor growth inhibition with treatment/control (T/C) ratios of 51% and 19%, respectively.
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    Apoptosis
  • Recptor
    Apoptosis|EGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1661854-97-2
  • Formula Weight
    396.44
  • Molecular Formula
    C23H20N6O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:125 mg/mL (315.31 mM)
  • SMILES
    CC1=C[C@@H](CN2C1=C(C3=C(N=CN=C32)N)C4=CC5=CC=CC=C5N=C4)NC(=O)C=C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Hasako S, et al. TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations. Mol Cancer Ther. 2018 Aug;17(8):1648-1658.
molnova catalog
related products
  • N-Hexanoyl-D-sphingo...

    C6-ceramide, a ceramide pathway activator, shows activity against a variety of cancer cell lines. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects.

  • Lonicerin

    Lonicerin has antioxidant, anti-arthritic and antifungal activities, it can result in a combination therapy for the treatment of fungal arthritis due to C. albicans infection.

  • SACLAC

    SACLAC is a cysteine asparaginase activation inhibitor with antitumor activity that decreases AML cell viability, inhibits AML cell proliferation, increases AML cell death, and induces apoptosis of AML cells, and is used in the study of acute myeloid leukemia and cancer.